Case Report

Bulky Pulmonary Mucosa-Associated Lymphoid Tissue Lymphoma Treated with Yttrium-90 Ibritumomab Tiuxetan

Figure 2

Chest X-ray (a) and CT scan ((b) and (c)) immediately before the administration of yttrium-90 ibritumomab tiuxetan. Chest X-ray (d) and CT ((e) and (f)) 2 months after its administration. Chest X-ray (g) and CT scan ((h) and (i)) 18 months after its administration. The abnormal shadow was significantly reduced after the administration of yttrium-90 ibritumomab tiuxetan. Radiation pneumonitis has not been reported for 18 months.
675187.fig.002a
(a)
675187.fig.002b
(b)
675187.fig.002c
(c)
675187.fig.002d
(d)
675187.fig.002e
(e)
675187.fig.002f
(f)
675187.fig.002g
(g)
675187.fig.002h
(h)
675187.fig.002i
(i)